UC Irvine at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
UC Irvine brings 1 presentation to ASH 2026 in New Orleans. Its program centres on chronic lymphocytic leukemia, from how the disease evolves to newer therapies. It also covers treating relapsed CLL and Richter transformation, and moving bispecific antibodies from later lines to frontline lymphoma care.
| Organization | ASH 2026 Attendance |
|---|---|
UC Irvine Irvine, CA | |
Public research university in Irvine, California; its medical center and cancer center are in nearby Orange. | Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. Session Chronic Lymphocytic Leukemia - From Clonal Evolution to Novel Therapies Chronic lymphocytic leukemia in the targeted-drug era, covering clonal evolution, choosing and sequencing therapies, and transformation into aggressive lymphoma. |
Instantly find 20 buyers from UC Irvine
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction